Wuhan Hvsen Biotechnology Co Ltd (SHE:300871) — Market Cap & Net Worth
Market Cap & Net Worth: Wuhan Hvsen Biotechnology Co Ltd (300871)
Wuhan Hvsen Biotechnology Co Ltd (SHE:300871) has a market capitalization of $617.42 Million (CN¥4.22 Billion) as of October 10, 2026. Listed on the SHE stock exchange, this China-based company holds position #11200 globally and #3145 in its home market, demonstrating a -2.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wuhan Hvsen Biotechnology Co Ltd's stock price CN¥20.91 by its total outstanding shares 201784357 (201.78 Million).
Wuhan Hvsen Biotechnology Co Ltd Market Cap History: 2020 to 2026
Wuhan Hvsen Biotechnology Co Ltd's market capitalization history from 2020 to 2026. Data shows change from $737.16 Million to $617.42 Million (-9.55% CAGR). Check 300871 stock price and chart for real-time trading data and today's change.
Wuhan Hvsen Biotechnology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wuhan Hvsen Biotechnology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Wuhan Hvsen Biotechnology Co Ltd (300871) cash conversion ratio for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.36x
Wuhan Hvsen Biotechnology Co Ltd's market cap is 0.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.42x
Wuhan Hvsen Biotechnology Co Ltd's market cap is 2.42 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $737.16 Million | $777.46 Million | $150.16 Million | 0.95x | 4.91x |
| 2021 | $795.20 Million | $996.22 Million | $132.87 Million | 0.80x | 5.98x |
| 2022 | $579.39 Million | $1.02 Billion | $52.71 Million | 0.57x | 10.99x |
| 2023 | $418.15 Million | $1.02 Billion | $16.78 Million | 0.41x | 24.92x |
| 2024 | $297.05 Million | $1.20 Billion | -$20.16 Million | 0.25x | N/A |
| 2025 | $612.10 Million | $1.68 Billion | $253.16 Million | 0.36x | 2.42x |
Competitor Companies of 300871 by Market Capitalization
Companies near Wuhan Hvsen Biotechnology Co Ltd in the global market cap rankings as of October 10, 2026. See Wuhan Hvsen Biotechnology Co Ltd balance sheet quality to understand what proportion of total assets are financed by equity.
Key companies related to Wuhan Hvsen Biotechnology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $129.29 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #366 globally with a market cap of $75.50 Billion USD.
- CSL Ltd (AU:CSL): Ranked #448 globally with a market cap of $63.11 Billion USD ( AU$89.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $129.29 Billion | $510.08 |
| #366 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $75.50 Billion | $746.54 |
| #448 | CSL Ltd | AU:CSL | $63.11 Billion | AU$183.84 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $225.00 |
Wuhan Hvsen Biotechnology Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Wuhan Hvsen Biotechnology Co Ltd's market cap moved from $737.16 Million to $ 617.42 Million, with a yearly change of -9.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥617.42 Million | +0.87% |
| 2025 | CN¥612.10 Million | +106.06% |
| 2024 | CN¥297.05 Million | -28.96% |
| 2023 | CN¥418.15 Million | -27.83% |
| 2022 | CN¥579.39 Million | -27.14% |
| 2021 | CN¥795.20 Million | +7.87% |
| 2020 | CN¥737.16 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 10th, 2026 the market cap of Wuhan Hvsen Biotechnology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $617.42 Million USD |
| MoneyControl | $617.42 Million USD |
| MarketWatch | $617.42 Million USD |
| marketcap.company | $617.42 Million USD |
| Reuters | $617.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Wuhan Hvsen Biotechnology Co Ltd
Wuhan Hvsen Biotechnology Co.,Ltd. is involved in the research and development, and manufacture of macrolides APIs and preparations in China and internationally. The company provides tylvalosin tartrate powders, and raw materials; florfenicol, cefquinome sulfate, and tildipirosin injections; and florfenicol powder/WSP, tylosin tartrate soluble powder, and tywasin premix products, as well as Tildi… Read more